Literature DB >> 22728481

Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study.

Ken Ikeda1, Takehisa Hirayama, Takanori Takazawa, Kiyokazu Kawabe, Yasuo Iwasaki.   

Abstract

OBJECTIVE: Previous studies have reported distinct serological profiles of lipid, urate and ferritin in Western patients with amyotrophic lateral sclerosis (ALS). We aimed to examine the levels of these serological factors and their relationship to disease progression in Japanese ALS patients.
METHODS: Ninety-two patients with definite or probable ALS who fulfilled the revised El Escorial criteria were analyzed for clinical and serological variables. Serological data at the time diagnosed with ALS were compared to those of 92 age/sex/body mass index-matched healthy controls.
RESULTS: Compared to controls, urate and creatinine (Cr) levels were decreased and ferritin levels were increased significantly in sera of male and female patients with ALS. Significant increases of serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride levels were found in female ALS patients. The annual decline of ALS Functional Rating Scale-Revised (ALS-FRS) and forced vital capacity (FVC) were inversely correlated with serum TC, LDL-C, Cr and urate levels, and were positively correlated with serum ferritin levels. Multivariate analysis showed that the rapid worsening of annual ALS-FRS and FVC was associated with serum levels of TC, LDL-C, Cr, urate and ferritin.
CONCLUSION: The present study indicated that serum levels of TC, LDL-C, Cr, urate and ferritin were correlated with clinical deterioration in ALS patients. These results are similar to those in Western patients. Metabolic and nutritional conditions of lipid, urate and iron could contribute to disease progression in ALS patients. Further studies investigating high nutrition diets and iron chelation for the treatment of ALS are warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728481     DOI: 10.2169/internalmedicine.51.7465

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  50 in total

1.  Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.

Authors:  Robert Küffner; Neta Zach; Raquel Norel; Johann Hawe; David Schoenfeld; Liuxia Wang; Guang Li; Lilly Fang; Lester Mackey; Orla Hardiman; Merit Cudkowicz; Alexander Sherman; Gokhan Ertaylan; Moritz Grosse-Wentrup; Torsten Hothorn; Jules van Ligtenberg; Jakob H Macke; Timm Meyer; Bernhard Schölkopf; Linh Tran; Rubio Vaughan; Gustavo Stolovitzky; Melanie L Leitner
Journal:  Nat Biotechnol       Date:  2014-11-02       Impact factor: 54.908

2.  Antecedent Disease is Less Prevalent in Amyotrophic Lateral Sclerosis.

Authors:  Cassie S Mitchell; Sabrina K Hollinger; Shivani D Goswami; Meraida A Polak; Robert H Lee; Jonathan D Glass
Journal:  Neurodegener Dis       Date:  2015-02-20       Impact factor: 2.977

Review 3.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

4.  Serum ferritin is a candidate biomarker of disease aggravation in amyotrophic lateral sclerosis.

Authors:  Jixu Yu; Nian Wang; Faying Qi; Xianjun Wang; Qiyi Zhu; Yucheng Lu; Huiling Zhang; Fengyuan Che; Wei Li
Journal:  Biomed Rep       Date:  2018-08-02

5.  Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference?

Authors:  Ji Won Yang; Sung-Min Kim; Hee-Juang Kim; Jee-Eun Kim; Kyung Seok Park; Seung-Hyun Kim; Kwang-Woo Lee; Jung-Joon Sung
Journal:  J Clin Neurol       Date:  2013-04-04       Impact factor: 3.077

6.  The PRO-ACT database: design, initial analyses, and predictive features.

Authors:  Nazem Atassi; James Berry; Amy Shui; Neta Zach; Alexander Sherman; Ervin Sinani; Jason Walker; Igor Katsovskiy; David Schoenfeld; Merit Cudkowicz; Melanie Leitner
Journal:  Neurology       Date:  2014-10-08       Impact factor: 9.910

7.  A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice.

Authors:  Sagit Golko-Perez; Tamar Amit; Orit Bar-Am; Moussa B H Youdim; Orly Weinreb
Journal:  Neurotox Res       Date:  2016-11-08       Impact factor: 3.911

Review 8.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

9.  Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.

Authors:  Franck Patin; Thomas Baranek; Patrick Vourc'h; Lydie Nadal-Desbarats; Jean-François Goossens; Sylviane Marouillat; Anne-Frédérique Dessein; Amandine Descat; Blandine Madji Hounoum; Clément Bruno; Hervé Watier; Mustafa Si-Tahar; Samuel Leman; Jean-Claude Lecron; Christian R Andres; Philippe Corcia; Hélène Blasco
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

10.  Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database.

Authors:  Sabrina Paganoni; Katharine Nicholson; James Chan; Amy Shui; David Schoenfeld; Alexander Sherman; James Berry; Merit Cudkowicz; Nazem Atassi
Journal:  Muscle Nerve       Date:  2017-09-21       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.